Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

NCT00192127
View directory record Official record
Conditions
Influenza
Interventions
FluMist, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2007 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer

NCT01354379
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
NB-1008, Fluzone IN
Biological
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

NCT06436703
View directory record Official record
Conditions
Influenza, Human
Interventions
Influenza ModRNA Vaccine, Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
32
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

NCT04451954
View directory record Official record
Conditions
Influenza Immunisation, Healthy Volunteers
Interventions
Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 15, 2026, 5:38 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children

NCT07870330
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Fluarix Trivalent
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
9 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Modesto, California • Aurora, Colorado • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

NCT01691339
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Boca Raton, Florida • South Miami, Florida • Council Bluffs, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Efficacy of Communication Modalities for Promoting Flu Shots

NCT05509270
View directory record Official record
Conditions
Influenza Vaccination, Health Promotion, Health Behavior, Risk Reduction
Interventions
Letter, Patient portal, SMS
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
43,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 15, 2026, 5:38 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

NCT07287137
View directory record Official record
Conditions
COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 79 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Open-Label Influenza Vaccine Evaluation

NCT02872311
View directory record Official record
Conditions
Immune Response
Interventions
High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine, Recombinant Influenza vaccine
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
65 Years to 74 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Collaborative Efforts to Increase Flu Vaccination

NCT01403649
View directory record Official record
Conditions
Influenza, Collaboration
Interventions
Private/public collaboration to increase flu vaccination, Usual care
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 18 Years
Enrollment
117,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
27
States / cities
Aurora, Colorado • Brighton, Colorado • Broomfield, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 15, 2026, 5:38 PM EDT
Completed No phase listed Observational

Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites

NCT04288921
View directory record Official record
Conditions
Influenza, Human, Respiratory Syncytial Virus Infections
Interventions
Swab
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
20
States / cities
Birmingham, Alabama • Encinitas, California • Madera, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination

NCT00889889
View directory record Official record
Conditions
Influenza
Interventions
Cell-Derived Trivalent Subunit Influenza Vaccine, Placebo
Biological
Lead sponsor
Abbott Biologicals
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
15
States / cities
Jacksonville, Florida • Pembroke Pines, Florida • South Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

NCT00391768
View directory record Official record
Conditions
Influenza
Interventions
oseltamivir (Tamiflu®)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 23 Months
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

NCT00943631
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 15, 2026, 5:38 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Human Influenza Transmission Study Using Naturally Infected Community Donors

NCT07814495
View directory record Official record
Conditions
Influenza
Interventions
Influenza Donor Visit, Influenza Recipient Inpatient Exposures Sessions
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza

NCT01390025
View directory record Official record
Conditions
Influenza, Human
Interventions
TCN-032, Placebo
Biological
Lead sponsor
Theraclone Sciences, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Statin Therapy in Acute Influenza

NCT02056340
View directory record Official record
Conditions
Influenza
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

NCT01205581
View directory record Official record
Conditions
HIV, Cancer
Interventions
Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

NCT02594189
View directory record Official record
Conditions
Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Interventions
Live recombinantly derived A/Bethesda/MM1/H3N2 virus
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Vaccination Uptake (VAX) in PD

NCT02874274
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Standard of Care, Home Visit Program (HVP)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT05050318
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine

NCT02212990
View directory record Official record
Conditions
Fever
Interventions
Acetaminophen Arm, Placebo Arm, Ibuprofen Arm
Other
Lead sponsor
Duke University
Other
Eligibility
6 Months to 47 Months
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 15, 2026, 5:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age

NCT01985997
View directory record Official record
Conditions
Observation Safety
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
Not listed
Enrollment
95,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 15, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

NCT02473510
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 15, 2026, 5:38 PM EDT